Jpmorgan Chase & CO Candel Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 10,426 shares of CADL stock, worth $53,902. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,426
Previous 9,051
15.19%
Holding current value
$53,902
Previous $62,000
45.16%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding CADL
# of Institutions
75Shares Held
15.6MCall Options Held
977KPut Options Held
521K-
Baker Bros. Advisors LP New York, NY2.98MShares$15.4 Million0.29% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.94MShares$10 Million9.1% of portfolio
-
Northpond Ventures, LLC1.94MShares$10 Million48.35% of portfolio
-
Braidwell LP Stamford, CT1.6MShares$8.27 Million0.78% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.34MShares$6.92 Million0.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $149M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...